Cited by 1,930Erythropoietin and Anemia TreatmentDialysis and Renal Disease ManagementBlood transfusion and management

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Open access

Besarab, Anatole, Bolton, W. Kline, Browne, Jeffrey K., Egrie, Joan C., Nissenson, Allen R., Okamoto, Douglas M., Schwab, Steve J., Goodkin, David A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199808273390903

Open this paper in CoChat — free account Open PDF

Abstract

BackgroundIn patients with end-stage renal dis- ease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. MethodsWe studied 1233 patients with clinical ev- idence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study.The median duration of treatment was 14 months.The primary end point was the length of time to death or a first nonfatal myocardial infarction. ResultsAfter 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the lowhematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9).Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted.The causes of death in the two groups were similar.The mortality rates decreased with increasing hematocrit values in both groups.The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. ConclusionsIn patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.(N

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199808273390903

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citation
Impact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
(1990) · BMJ · doi:10.1136/bmj.300.6724.573 · Cited by 427
The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 401

Show all 28 references

Research works printed but not linked: 8

Pascual J, 1991, Clin Nephrol, 35, 280
Eschbach JW, 1993, J Am Soc Nephrol, 4, 425
Collins A, 1994, J Am Soc Nephrol, 5, 439
Nissenson AR, 1996, J Am Soc Nephrol, 7, 1459
Barany P, 1996, J Am Soc Nephrol, 7, 1472
Benz RL, 1996, J Am Soc Nephrol, 7, 1473
Hoen B, 1995, Nephrol Dial Transplant, 10, 377
Collins A, 1997, J Am Soc Nephrol, 8, 190A

Sorted by citations

Items 801–900 of 1,000

Cardiac disease in chronic uremia
Parfrey, P. S. (2004) · Springer eBooks · doi:10.1007/978-1-4020-2275-3_30 · Cited by 17
Anaemia and heart failure
Coats, A. J. S. (2004) · Heart · doi:10.1136/hrt.2003.012997 · Cited by 17
Hemoglobin target in chronic kidney disease: a pediatric perspective
Keithi-Reddy, S. R., & Singh, A. K. (2008) · Pediatric Nephrology · doi:10.1007/s00467-008-0902-2 · Cited by 17
Erythropoiesis-Stimulating Agents and Mortality
Drüeke, T. B., & Massy, Z. A. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019030266 · Cited by 17
The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI
Demetz, G., Laux, M., Scherhag, A., Hoekstra, T., Suttorp, M. M., Dekker, F., Roest, M., Marcus-Kalish, M., Mittelman, M., & Ott, I. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-18 · Cited by 16
Different risk factors are associated with vascular access patency after construction and percutaneous transluminal angioplasty in patients starting hemodialysis
Yoshida, M., Doi, S., Nakashima, A., Kyuden, Y., Kawai, T., Kawaoka, K., Takahashi, S., Ueno, T., Nishizawa, Y., & Masaki, T. (2020) · The Journal of Vascular Access · doi:10.1177/1129729820959934 · Cited by 16
Optimal hematocrit theory: a review
Šitina, M., Stark, H., & Schuster, S. (2024) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00034.2024 · Cited by 16
Treatment of Heart Failure in Long-term Dialysis Patients: A Reappraisal
Wang, A. Y.-M., & Sanderson, J. E. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.01.014 · Cited by 16
Estimating cerebral blood volume with expanded vascular space occupancy slice coverage
Glielmi, C. B., Schuchard, R. A., & Hu, X. P. (2009) · Magnetic Resonance in Medicine · doi:10.1002/mrm.21979 · Cited by 16
Erythropoietic Agents and the Elderly
Agarwal, N., & Prchal, J. T. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.06.007 · Cited by 16
Erythropoietin Attenuates the Development of Experimental Autoimmune Myocarditis
Hirose, S.-I., Takahashi, M., Ogawa, R., Morimoto, H., Izawa, A., Satō, H., Ise, H., Hongo, M., & Ikeda, U. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6005-7 · Cited by 16
Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes
Levin, A., Lancashire, W., & Fassett, R. G. (2013) · Kidney International · doi:10.1038/ki.2013.91 · Cited by 16
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Drüeke, T. B. (2018) · Renal Replacement Therapy · doi:10.1186/s41100-018-0187-2 · Cited by 16
Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
Hayashi, T., Kato, H., Tanabe, K., Nangaku, M., Hirakata, H., Wada, T., Satō, H., Yamazaki, Y., Masaki, T., Kagimura, T., et al. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01969-7 · Cited by 16
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
Ishii, T., Tanaka, T., & Nangaku, M. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s293879 · Cited by 16
Erythropoiesis stimulating agent recommendation model using recurrent neural networks for patient with kidney failure with replacement therapy
Yun, H., Lee, G., Jeon, M. J., Kim, H. W., Joo, Y. S., Kim, H., Chang, T. I., Park, J. T., Han, S. H., Kang, S., et al. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104718 · Cited by 16
Current Status of Renal Anemia Pharmacotherapy—What Can We Offer Today
Borawski, B., Małyszko, J. S., Kwiatkowska, M., & Małyszko, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184149 · Cited by 16
Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients
Maekawa, K., Shoji, T., Emoto, M., Okuno, S., Yamakawa, T., Ishimura, E., Inaba, M., & Nishizawa, Y. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm929 · Cited by 16
Choice of dialysis modality
Mehrotra, R. (2011) · Kidney International · doi:10.1038/ki.2011.262 · Cited by 16
Erythropoietic stimulating agents
Testa, U. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903499273 · Cited by 17
Major Declines in Epoetin Dosing after Prospective Payment System Based on Dialysis Facility Organizational Status
Thamer, M., Zhang, Y., Kaufman, J. S., Kshirsagar, O. S., Cotter, D. J., & Hernán, M. Á. (2014) · American Journal of Nephrology · doi:10.1159/000370334 · Cited by 16
How to diagnose and treat coronary artery disease in the uraemic patient: an update
Elsner, D. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.6.1103 · Cited by 16
Cost-effectiveness of continuous erythropoietin receptor activator in anemia
Schmid, H. (2014) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s46930 · Cited by 16
High Ferritin Level and Malnutrition Predict High Risk of Infection-Related Hospitalization in Incident Dialysis Patients: A Japanese Prospective Cohort Study
Kato, S., Lindholm, B., Yuzawa, Y., Tsuruta, Y., Nakauchi, K., Yasuda, K., Sugiura, S., Morozumi, K., Tsuboi, N., & Maruyama, S. (2016) · Blood Purification · doi:10.1159/000445424 · Cited by 16
Current and future chemical therapies for treating anaemia in chronic kidney disease
Locatelli, F., Vecchio, L. D., & Luise, M. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1323872 · Cited by 16
The Medicare Access and CHIP Reauthorization Act: Implications for Nephrology
Lin, E., MaCurdy, T. E., & Bhattacharya, J. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017040407 · Cited by 16
Kidney Disease and Anemia in Elderly Patients
Musio, F. M. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.03.009 · Cited by 16
A new insight into the treatment of renal anemia with HIF stabilizer
Kuriyama, S., Maruyama, Y., & Honda, H. (2020) · Renal Replacement Therapy · doi:10.1186/s41100-020-00311-x · Cited by 16
Erythropoietin treatment and the risk of hip fractures in hemodialysis patients
Suresh, S., Wright, E. C., Wright, D. G., Abbott, K. C., & Noguchi, C. T. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4297 · Cited by 16
Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective
Fishbane, S. N. (2008) · Kidney International · doi:10.1038/ki.2008.467 · Cited by 16
THE USE OF PRETRANSPLANT ERYTHROPOIETIN TO NORMALIZE HEMOGLOBIN LEVELS HAS NO DELETERIOUS EFFECTS ON RENAL TRANSPLANTATION OUTCOME1
Linde, T., Ekberg, H., Forslund, T., Furuland, H., Holdaas, H., Nyberg, G., Tyd�n, G., Wahlberg, J. A., & Danielson, B. G. (2001) · Transplantation · doi:10.1097/00007890-200101150-00013 · Cited by 16
Cardiovascular Effects of Home Intensive Hemodialysis
Chan, C. T. (2009) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2009.02.003 · Cited by 16
Anemia and diabetic nephropathy
Ritz, E. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0081-0 · Cited by 16
Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older
Ibrahim, H. N., Ishani, A., Guo, H., & Gilbertson, D. T. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp213 · Cited by 16
A need for an individualized approach to end-stage renal disease patients
Horl, W. H. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.suppl_6.17 · Cited by 16
Opportunities to improve the management of anemia in peritoneal dialysis patients: lessons from a national study in routine clinical practice
Portolés, J. M., Salazar, M. L. S., Peña, O. G., Domínguez, S. G., Vera, M., Caro, J., García, A. H., Vila, M. A. M., Huete, M. J. E., Barrios, R. H. S., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad152 · Cited by 15
Effect of Anemia on Physical Function and Physical Activity in CKD: The National Health and Nutrition Examination Survey, 1999–2016
Farag, Y. M. K., Blasco‐Colmenares, E., Zhao, D., Sanon, M., Güallar, E., & Finkelstein, F. O. (2023) · Kidney360 · doi:10.34067/kid.0000000000000218 · Cited by 15
Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia
Joharapurkar, A. A., Pandya, V. B., Patel, H., Jain, M., & Desai, R. C. (2024) · Frontiers in Nephrology · doi:10.3389/fneph.2024.1459425 · Cited by 15
How Can Erythropoeitin‐Stimulating Agent Use be Reduced in Chronic Dialysis Patients?
Kovesdy, C. P. (2013) · Seminars in Dialysis · doi:10.1111/sdi.12107 · Cited by 15
A Pilot Study of Darbepoetin Alfa for Prophylactic Neuroprotection in Aortic Surgery
Messe, S. R., McGarvey, M. L., Bavaria, J. E., Pochettino, A. A., Szeto, W. Y., Cheung, A. T., Leitner, E. G., Miller, S. W., & Kasner, S. E. (2012) · Neurocritical Care · doi:10.1007/s12028-012-9710-4 · Cited by 15
Responsiveness to Erythropoiesis-Stimulating Agents in Chronic Kidney Disease: Does Geography Matter?
Nicola, L. D., Locatelli, F., Conte, G., & Minutolo, R. (2014) · Drugs · doi:10.1007/s40265-013-0175-3 · Cited by 15
Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients
Hung, A. M., Limkunakul, C., Placido, J. S., Siew, E. D., Ellis, C. D., Shintani, A., & Ikizler, T. A. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0070-3 · Cited by 15
Hemoglobin level and risk of hospitalization and mortality in children on peritoneal dialysis
Dahlinghaus, E. K., Neu, A. M., Atkinson, M. A., & Fadrowski, J. J. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2872-x · Cited by 15
Clinical Outcomes of Erythropoietin Use in Heart Failure Patients With Anemia of Chronic Kidney Disease
Jackevicius, C. A., Fan, C. S., & Warner, A. L. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.02.001 · Cited by 15
Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study
Povsic, T. J., Sloane, R. J., Pieper, C. F., Pearson, M. P., Peterson, E. D., Cohen, H. J., & Morey, M. C. (2015) · The Journals of Gerontology Series A · doi:10.1093/gerona/glv180 · Cited by 15
Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
Diebold, M., & Kistler, A. D. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1263-8 · Cited by 15
Special Article: The Normal Hematocrit Cardiac Trial Revisited
Goodkin, D. A. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00620.x · Cited by 15
Self-citation
Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs
Kleophas, W., Karaboyas, A., Li, Y., Bommer, J., Reichel, H., Walter, A., Icks, A., Rump, L. C., Pisoni, R. L., Robinson, B. M., et al. (2013) · Kidney International · doi:10.1038/ki.2013.143 · Cited by 15
An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost
Teehan, G. S., & Benz, R. L. (2011) · Anemia · doi:10.1155/2011/623673 · Cited by 15
Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients
Derebail, V. K., Nachman, P. H., Key, N. S., Ansede, H., Falk, R. J., Rosamond, W. D., & Kshirsagar, A. V. (2011) · Kidney International · doi:10.1038/ki.2011.247 · Cited by 15
Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new
Quarles, L. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67203 · Cited by 15
Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods
Iseki, K., Tokuyama, K., Shiohira, Y., Higa, A., Hirano, H., Toma, S., Kohagura, K., & Ueda, S. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0116-8 · Cited by 15
Recombinant human erythropoietin in the treatment of nonrenal anemia
Heuser, M., & Ganser, A. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1086-5 · Cited by 15
Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis
Thaweethamcharoen, T., Sakulbumrungsil, R. C., Nopmaneejumruslers, C., & Vasuvattakul, S. (2014) · Value in Health Regional Issues · doi:10.1016/j.vhri.2014.01.001 · Cited by 15
Anemia and Heart Failure in Chronic Kidney Disease
Locatelli, F., Pozzoni, P., & Vecchio, L. D. (2005) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.05.008 · Cited by 15
Survival Benefits with Vitamin D Receptor Activation
Kovesdy, C. P. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02590310 · Cited by 15
The FDA's Perspective on the Risk for Rapid Rise in Hemoglobin in Treating CKD Anemia
Singh, A. K. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00490110 · Cited by 15
Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
Saglimbene, V. M., Palmer, S. C., Craig, J. C., Ruospo, M., Nicolucci, A., Tonelli, M. A., Johnson, D. W., Lucisano, G., Williams, G., Valentini, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172735 · Cited by 15
El modelo de control de anemia: ¿ayuda al nefrólogo en la decisión terapéutica para el manejo de la anemia?
Bucalo, M. L., Barbieri, C., Roca, S., Titapiccolo, J. I., Romero, M. S. R., Ramos, R., Pérez, M. A., Manzano, D., Mari, F., & Molina, M. (2018) · Nefrología · doi:10.1016/j.nefro.2018.03.004 · Cited by 15
THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Hemodynamic Cardiovascular Risk Factors in Chronic Kidney Disease: What are the Effects of Intervention?
McMahon, L. P. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16029.x · Cited by 15
Total Dose Iron Dextran Infusion in Cancer Patients: Is it SaFe2+?
Gilreath, J. A., Stenehjem, D. D., & Rodgers, G. M. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0066 · Cited by 15
Peginesatide for the treatment of renal disease-induced anemia
Schmid, H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.780695 · Cited by 15
Anemia of chronic disease: Past, present, and future
Toto, R. D. (2003) · Kidney International · doi:10.1046/j.1523-1755.64.s87.4.x · Cited by 15
Is Nephrology More at Ease Than Oncology with Erythropoiesis-Stimulating Agents? Treatment Guidelines and an Update on Benefits and Risks
Locatelli, F., & Gascón, P. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-s1-57 · Cited by 15
Effect of normovolemic hematocrit changes on blood pressure and flow
Bonnin, P., Vilar, J., & Levy, B. I. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.01.050 · Cited by 15
Pharmacotherapy of end-stage renal disease
Schmid, H., Schiffl, H., & Lederer, S. R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903544494 · Cited by 15
Association Between Nephrologist Ownership of Dialysis Facilities and Clinical Outcomes
Lin, E., McCoy, M. S., Liu, M., Lung, K. I., Rapista, D., Berns, J. S., & Kanter, G. P. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.5002 · Cited by 14
Association between hemoglobin level and mortality in patients undergoing maintenance hemodialysis: a nationwide dialysis registry in Japan
Kosugi, T., Hasegawa, T., Imaizumi, T., Nishiwaki, H., Honda, H., Ito, Y., Tsuruya, K., Abe, M., Hanafusa, N., & Kuragano, T. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02632-9 · Cited by 14
Erythropoietin-Induced Erythroid Precursor Pool Depletion Causes Erythropoietin Hyporesponsiveness
Yan, X., Ait‐Oudhia, S., & Krzyżański, W. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0938-7 · Cited by 14
Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients
Chan, K., Moran, J., Hlatky, M. A., & Lafayette, R. A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn780 · Cited by 14
Cinética de la hemoglobina y pronóstico a largo plazo en insuficiencia cardiaca
Díez‐López, C., Lupón, J., de Antonio, M., Zamora, E., Domingo, M., Santesmases, J., Troya, M. I., Boldo, M., & Bayés‐Genís, A. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.02.033 · Cited by 14
Association between Severe Anemia and Outcomes of Hemodialysis Vascular Access
Locham, S. S., Mathlouthi, A., Aridi, H. D., Nejim, B. J., & Malas, M. B. (2019) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2019.06.016 · Cited by 14
Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia
Zhu, Y., Tang, Y., He, H., Hu, P., Sun, W., Jin, M., Wang, L., & Xu, X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.919352 · Cited by 14
Hemodialysis facility star rating affects mortality in chronic hemodialysis patients: a longitudinal observational cohort study
Park, H. C., Choi, H. Y., Kim, D. H., Cho, A., Kwon, Y. E., Ryu, D., Yang, K. H., Won, E. M., Shin, J. H., Kim, J., et al. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.039 · Cited by 14
Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial
Muirhead, N., Keown, P. A., Churchill, D. N., Poulin-Costello, M., Gantotti, S., Lei, L., Gitlin, M. D., & Mayne, T. J. (2010) · Hemodialysis International · doi:10.1111/j.1542-4758.2010.00508.x · Cited by 14
Role of Vascular Function in Predicting Arteriovenous Fistula Outcomes: An Observational Pilot Study
MacRae, J. M., Ahmed, S. B., Hemmelgarn, B. R., Sun, Y., Martin, B., Roifman, I., & Anderson, T. J. (2015) · Canadian Journal of Kidney Health and Disease · doi:10.1186/s40697-015-0055-8 · Cited by 14
Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: Methods and data comparison results
Peter, W. L. S., Liu, J., Weinhandl, E. D., & Qiao, F. A. N. (2008) · Hemodialysis International · doi:10.1111/j.1542-4758.2008.00312.x · Cited by 14
Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series
Thamer, M., Zhang, Y., Lai, D., Kshirsagar, O. S., & Cotter, D. J. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-172 · Cited by 14
Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005–13
Birnie, K., Caskey, F. J., Ben‐Shlomo, Y., Sterne, J. A. C., Gilg, J. A., Nitsch, D., & Tomson, C. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw043 · Cited by 14
Red cell physiology and signaling relevant to the critical care setting
Said, A. S., Rogers, S. C., & Doctor, A. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000225 · Cited by 14
Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost
Sagheb, M. M., Fallahzadeh, M. A., Moaref, A., Fallahzadeh, M. H., & Dormanesh, B. (2016) · Nephro-Urology Monthly · doi:10.5812/numonthly.38495 · Cited by 14
Emerging drugs for the treatment of kidney disease-induced anemia
Małyszko, J., & Małyszko, J. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220537 · Cited by 14
Anemia in conventional hemodialysis: Finding the optimal treatment balance
Hasegawa, T., Koiwa, F., & Akizawa, T. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12719 · Cited by 14
Achievement of renal anemia KDIGO targets by two different clinical strategies – a European hemodialysis multicenter analysis
Drożdż, M., Weigert, A. L. L., Silva, F. L., Frazão, J. M., Alsuwaida, A., Krishnan, M., Kleophas, W., Brzόsko, S., Johansson, F. K., & Jacobson, S. H. (2019) · BMC Nephrology · doi:10.1186/s12882-018-1196-7 · Cited by 14
Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: Results of a double-blind, placebo-controlled randomized trial
Tang, Y.-D., Rinder, H. M., & Katz, S. D. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.06.036 · Cited by 14
Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients
Pozzoni, P., Pozzi, M., Vecchio, L. D., & Locatelli, F. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2004.06.012 · Cited by 14
Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients
Chan, K., Lafayette, R. A., Whittemore, A. S., Hlatky, M. A., & Moran, J. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn172 · Cited by 14
Why is an infection control program needed in the hemodialysis setting?
Arduino, M. J., & Tokars, J. I. (2005) · PubMed · Cited by 14
Course of Vascular Access and Relationship with Treatment of Anemia
Portolés, J. M., López–Gómez, J. M., Gruss, E., & Aljama, P. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01320307 · Cited by 14
Inadequate Treatment of Cardiovascular Disease and Cardiovascular Disease Risk Factors in Dialysis Patients: A Commentary
Culleton, B. F., & Hemmelgarn, B. R. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17360.x · Cited by 14
Erythropoietin and iron use in peritoneal dialysis patients: Report from the 1997 HCFA end-stage renal disease core indicators project
Bailie, G. R., Frankenfield, D. L., Prowant, B. F., McClellan, W., & Rocco, M. V. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70163-0 · Cited by 14
Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit
Murphy, S. T., & Parfrey, P. S. (1999) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199909000-00007 · Cited by 14
Quality of Life in CKD Patients Treated With Erythropoiesis-Stimulating Agents
Parfrey, P. S., & Wish, T. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.12.014 · Cited by 14
Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial
Mark, P. B., Jhund, P. S., Walters, M. R., Petrie, M. C., Power, A. J., White, C., Robertson, M., Connolly, E., Anker, S. D., Bhandari, S., et al. (2021) · Kidney360 · doi:10.34067/kid.0004272021 · Cited by 13
A spotlight on using HIF-PH inhibitors in renal anemia
Odawara, M., Nishi, H., & Nangaku, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2378903 · Cited by 14
State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists
Covic, A. C., & Abraham, I. L. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1042-9 · Cited by 13
Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
Berns, J. S. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32833c3cc7 · Cited by 13
Extended dosing of darbepoetin alfa in peritoneal dialysis patients
Feriani, M., Meester, J. M. D., McMahon, L. P., Rottembourg, J. B., Bridges, I. M., Farouk, M., & Pronai, W. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-13 · Cited by 13
Is there a deleterious effect of erythropoietin in end-stage renal disease?
Singh, A. K. (2011) · Kidney International · doi:10.1038/ki.2011.190 · Cited by 13
Correlation between CRP and early failure of arteriovenous fistula (AVF).
Zadeh, M. K., Mohammadipour, S., & Omrani, Z. (2015) · PubMed Central · Cited by 13

Authors: Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A.
Affiliations: Henry Ford Hospital (US)
University of Virginia Health System (US)
Amgen (United States) (US)
University of California, Los Angeles (US)
Duke University (US)
ORCID: Bolton, W. Kline
Goodkin, David A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-08-27
Volume: 339
Issue: 9
Pages: 584-590
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199808273390903
OpenAlex: W2331665138
Cited by: 1,930
References: 28
Citations by year: 2026: 23 · 2025: 33 · 2024: 36 · 2023: 44 · 2022: 52 · 2021: 82 · 2020: 59 · 2019: 61 · 2018: 59 · 2017: 68 · 2016: 75 · 2015: 56 · 2014: 89 · 2013: 102 · 2012: 99
FWCI: 21.09
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Health Sciences › Medicine › Hematology › Blood transfusion and management
Keywords: hematocrit, recombinant human erythropoietin, epoetin, hemodialysis, end-stage renal disease, anemia, congestive heart failure, ischemic heart disease, myocardial infarction, mortality, dialysis adequacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks